In this study, we explored the potential association between estrogen receptor b (ERb) and disease in a group of bulimic women. Eating disorders are much more common in females than in males, suggesting a possible role for female sex hormone signalling in the pathogenesis of these diseases. Furthermore, estrogen has been implicated in appetite regulation. The occurrence of menstrual disturbances is also increased in bulimic women. We studied 76 bulimic women and 60 controls, and found an association between two common polymorphisms in the ERb gene with disease in this group of bulimic women. More detailed characterisation of the ERb gene identified a novel variant changing the primary structure of ERb protein in one bulimic patient. An initial functional characterization of this variant did not reveal any differences compared to the wild-type protein. Our findings point towards a possible role of ERb and/or neighboring genes in the etiology of disease in bulimic patients.
Eating disorders are much more common in females than in males 1 , suggesting a possible role for female sex hormone signalling in the etiology of disease. Estrogen has also been implicated in feeding behavior and is known to inhibit feeding in animal experiments. 2, 3 There is evidence that estradiol acts to increase the activity of the cholecystokinin (CCK) satiation signalling pathway. 2, 3 The satiating potency of endogenous CCK is increased during estrus in normal rats and by estradiol treatment in ovariectomized rats. [3] [4] [5] In bulimic women, the occurrence of menstrual irregularities is increased, despite the maintenance of normal weight. 6 Little is, however, known about the role of estradiol in disordered eating in women. Estrogen receptor b (ERb) is expressed in many areas of the central nervous system in rats. 7 In the hypothalamus, a brain area known to be involved in the regulation of appetite and satiety, both ERa and ERb are expressed. 7 Recently, ERb was found to be the receptor regulating the anorectic action of estrogen in mice. 8 The involvement of a genetic component in the etiology of bulimic disease is suggested from studies of families with bulimic patients and twins. [9] [10] [11] [12] [13] [14] [15] However, the actual genes involved in the pre-disposition for disease remain to be elucidated. So far, only a few variants of the ERb gene have been reported and characterized with regard to allele frequency. [16] [17] [18] [19] Rosenkranz et al 16 performed a systematic mutation screening of ERb in probands of different weight extremes and identified five different genetic variants. Only two of these appeared at an allele frequency over 1% for the less common allele. These SNPs, 1082 G-A and 1730 A-G, did not display association with the phenotypes under study. These SNPs have later been analyzed for association between ERb and ovulatory dysfunctions, 19 including polycystic ovary syndrome (PCOS) and could be associated with ovulatory defects in patients with unknown causes of disease. Other studies have investigated the possible association between a dinucleotide repeat polymorphism located in the flanking region of the human ERb gene and systemic blood pressure or bone mineral density, respectively. 17, 18 A possible association between this polymorphism and hypertension in Japanese women was reported. 18 The dinucleotide repeat was also suggested to be associated with bone mineral density. 17 Based on the potential role of female sex hormone signalling for the development of binge-eating together with the fact that bulimic women frequently present menstrual irregularities, we hypothesized that a reduction in ERb function might contribute to disease.
Materials and methods

Subjects
Blood samples from 76 Swedish patients diagnosed with bulimia nervosa (BN) or eating disorders not otherwise specified (EDNOS), with bulimia as the predominating symptom (referred to as bulimic patients in this paper), and 60 healthy female controls (body mass index (BMI) and age were matched to the bulimic patients) were collected at the Department of Obstetrics and Gynaecology at the Karolinska Hospital. Patients were diagnosed by interview and met the criteria for BN and EDNOS with bulimic symptoms according to DSM-IV-R. 20 A total of 48 patients were diagnosed with BN and 28 patients were diagnosed with EDNOS. Menstrual status was classified as regular monthly periods, amenorrhea; no bleeding for the last 3 months or oligomenorrhea; periods at an interval exceeding 6 weeks. Among the bulimic patients, 27 (36%) had menstrual disturbances (amenorrhea or oligomenorrhea), whereas only two (3%) of the controls had oligomenorrhea. 
Mutation analysis
DNA amplification Genomic DNA was prepared using a QIAamp s DNA MiniKit (QIAGEN). All polymerase chain reaction (PCR) amplifications were performed using AmpliTaq Gold (Roche) according to standard protocols. All primers were designed to cover intron-exon borders of the ERb gene; see Table 1 .
SNP scoring using RFLP analysis Three ERb polymorphisms were studied: a G-A change at position 1082 in exon 5 (reported as rs1256049 in the SNPper database (http://snpper.chip.org/)) creating a recognition site for RsaI, a G-A change at position 1730 in the 3 0 UTR of exon 8 creating an AluI site, and a G-A change at ERb cx þ 56 (rs928554) generating a restriction site for Tsp509I. ERb cx þ 56 is located 56 bases 3 0 of the coding part of ERb cx exon 9. Restriction enzyme assays were performed according to standard procedures. Genotypes were scored twice.
Statistical analysis Allele frequencies of the ERb polymorphisms were compared between the patient and control groups using the w 2 test. The statistical analyses were performed using Epi Info 2000 software. Haplotypes in population samples were inferred using the Phase software. 21 Linkage disequilibrium between adjacent markers was estimated as r
, where a and b are two loci with allele frequencies p A , p a , p B , p b and haplotype frequencies p AB , p ab , p Ab , p aB .
22
Denaturing high-performance liquid chromatography Mutation analysis was undertaken using temperaturemodulated heteroduplex analysis (TMHA) on an automated high-performance liquid chromatography (HPLC) instrument equipped with a DNASep column (Transgenomic). Heteroduplex and homoduplex generations were performed by heating the PCR products to 951C for 5 min and slowly cooling by 1.51C/min for 47 cycles. A volume of 5 ml of each PCR product was analyzed using the WAVE s system (Transgenomic). DNA was eluted with a mixture containing 0.1 mol/l triethylamine acetate and 0.1 mol/l triethylamine acetate þ 25% acetonitrile at a flow rate of 0.9 ml/ min. The WAVEMAKER TM Software package (Transgenomic) suggested mobile-phase gradients and a melting temperature based on the exon sequence. Exons with an abnormal TMHA profile were sequenced and compared with the published genomic sequence of the ERb gene. Plasmid constructs hERb 530 cDNA cloned into the EcoRI sites of the pSG5 expression vector (Stratagene, La Jolla, CA, USA) was used as template for mutagenesis. Mutant construct (pSG5-hERb 530 R221G) was produced by the introduction of a 1 bp substitution (A-G) using the QuickChange XL sitedirected mutagenesis kit (Stratagene). The substitution was confirmed by DNA sequencing.
Cell culture and transfection HEK 293 cells were cultured in a 1 : 1 ratio of Ham's Nutrient mixture F12 (Invitrogen) and DMEM (Invitrogen) supplemented with 5% FBS and 100 U penicillin/ml and 100 mg streptamycin/ml. Cells were plated in 24-well plates 24 h prior to transfection. Transfections using the Superfect reagent (QIAGEN) were performed according to the manufacturer's protocol. 0.8 mg of 2 Â ERE-TK-LUC was cotransfected with 0.032 mg of pSG5-hERb 530 or pSG5-hERb 530 R221G. A pRL-TK control plasmid, containing the Renilla luciferase gene, was used as an internal control. The pSG5 vector was used to equalize plasmid concentrations. Upon transfection, the medium was changed to a phenol-red-free 1 : 1 mixture of F12 and DMEM containing 5% dextran-coated charcoal-treated FBS and 100 U penicillin/ml and 100 mg streptamycin/ml. Hormone or vehicle in 0.1% EtOH was added simultaneously. Cells were harvested 24 h after transfection and luciferase activities were determined using the Dual Luciferase Reporter Assay System (Promega) according to the manufacturer's protocol. Allele and genotype frequencies are shown in Table 2 . Genotype frequencies were in Hardy-Weinberg equilibrium among cases and controls, respectively. Estimated haplotypes and associated relative risk are shown in Table 3 . Haplotype analysis supports the fact that both studied ERb polymorphisms are associated with increased risk of disease independently.
Results
Association of polymorphisms in the ERb gene with disease in bulimic women
Linkage disequilibrium based on inferred haplotypes between 1730 and ERb cx were 0.41 and 0.37 in controls and cases, respectively. Linkage disequilibrium based on inferred haplotypes between 1082 and 1730 were o0.05 for both cases and controls.
This study shows an association between disease and the 1730 G-A and ERb cx þ 56 G-A ERb gene variants for this group of bulimic women.
Identification of novel variants of the ERb gene
The association described above could exist either because changes at the nucleotide positions in question affect ERb function or because they are in linkage disequilibrium with functional changes that might occur in ERb or a neighboring gene. To investigate the latter possibility, we screened all exons of the ERb gene in the bulimic patients and controls for novel variants. TMHA was chosen to screen the exons encoding the full-length ERb protein for potential new variants. Artificial mutations were generated to validate methods. Direct sequencing was used to confirm abnormal TMHA profiles and to determine the identity of the variant. The polymorphisms in exons 5 and 8, studied above result in a background in this analysis when trying to identify novel variants. However, this background of heterozygotes for known SNPs can be eliminated using subsequent restriction enzyme analysis to eliminate the known polymorphisms. Figure 3 shows the TMHA profiles for exons 5 and 8, homozygous and heterozygous patterns. The variants, including frequencies, identified in this study are shown in Table 4 .
Interestingly, in one bulimia patient, a 661 A-G change was identified. The patient is heterozygous for the variant that leads to an amino-acid substitution, arginine 221 for glycine (R221G) (Figure 4 ). This variant has not been detected in our studies of 4200 subjects who were not part of this study (data not shown). As an initial test of the functional implications of this amino-acid substitution, this mutant receptor was analyzed in a transient transfection system ( Figure 5 ). However, this assay revealed no differences between the ERb wild type (WT) and ERb R221G proteins with regard to transcriptional activation. The other variants mentioned above do not affect the primary structure of the ERb protein. 
Discussion
In this study, we describe an association between polymorphisms in the ERb gene and disease in bulimic patients. Further analysis showed that both BN and EDNOS were independently associated with the ERb polymorphisms (data not shown). Furthermore, menstrual irregularities were not independently associated with the ERb polymorphisms (data not shown). Our clinical observations show no distinction between bulimic women with the risk allele and those without. Interestingly, ERb is located on chromosome 14q, in a region recently identified to meet the criterion for genome-wide suggestive linkage with BN. 23 However, a German study did not provide evidence for an association between BN and ERb polymorphisms. 16 Our finding points towards a possible role of ERb and/or neighboring genes in the etiology of disease in bulimic patients. Whether this role derives from its functions in peripheral and/or central systems will need to be addressed. It remains a formal possibility that these polymorphisms per se contribute to ERb function and the etiology of disease. As they are located in the 3 0 UTR, they could affect mRNA stability. However, more likely, these polymorphisms are in linkage disequilibrium with a functional change in the ERb gene or other genes. To test the latter possibility, we screened the ERb gene of bulimic patients and controls for variants. Our results are in accordance with previous studies showing a low degree of variation for the ERb gene, identifying only very few novel polymorphisms. Two new and rare intron variants were identified, ERb 8 À4 A-G (rs944050) and ERb 8 -68 C-T. However, since they do not change the primary structure of the ERb protein, and are most probably not involved in the splicing of ERb, they are not likely to be relevant for ERb protein function. Furthermore, they occur in both bulimic patients and control subjects ( Table 4) .
The 661 A-G variant identified in one bulimic patient changes the primary structure of the ERb protein. This patient was diagnosed EDNOS. This particular amino acid is conserved in the ERb protein in all sequenced species. Furthermore, this position is also conserved in ERa with regard to charge (arginine in ERb and lysine in ERa). The R221G mutation is situated in the hinge region of ERb. This part of the receptor is thought to constitute a flexible hinge between the DNA-binding domain and the ligandbinding domain. Although the R221G mutation is clearly not a common genetic variant causing EDNOS, this mutation might be of importance in the etiology of EDNOS in this particular patient who also had menstrual disturbance. Since this allele is rare, final proof for a causative effect of this mutation would be to show association between this allele and disease in a family study and to demonstrate a difference compared to the wild-type receptor in a functional assay. Evaluation of the functional characteristics of this variant in a transient transfection assay did not reveal impaired receptor function. However, this assay only measures a subset of ERb functions, and further studies will be needed to determine whether or not this variant behaves differently from the wildtype ERb protein. The fact that we only identified one rare variant of ERb does not exclude the possibility that ERb function is impaired in a larger group of these patients. Variations at the DNA level, affecting primary protein structure, are not the only cause of abnormal ERb receptor function; dysregulation at the transcriptional and/or translational levels leading to abnormal ERb protein levels remain other possibilities. 
